Related Experiment Video
Updated: Jul 10, 2025
Peptide Scanning-assisted Identification of a Monoclonal Antibody-recognized Linear B-cell Epitope
Published on: March 24, 2017
Design of MERS-CoV entry inhibitory short peptides based on helix-stabilizing strategies
Jichun Li1, Qing Li2, Shuai Xia3
1College of Chemical and Pharmaceutical Engineering, Hebei University of Science and Technology, 26 Yuxiang Street, Shijiazhuang 050018, China; State Key Laboratory of Toxicology and Medical Countermeasures, Beijing Institute of Pharmacology & Toxicology, 27 Tai-Ping Road, Beijing 100850, China.
Abstract:
Interaction between Middle East respiratory syndrome coronavirus (MERS-CoV) spike (S) protein heptad repeat-1 domain (HR1) and heptad repeat-2 domain (HR2) is critical for the MERS-CoV fusion process. This interaction is mediated by the α-helical region from HR2 and the hydrophobic groove in a central HR1 trimeric coiled coil. We sought to develop a short peptidomimetic to act as a MERS-CoV fusion inhibitor by reproducing the key recognition features of HR2 helix. This was achieved by the use of helix-stabilizing strategies, including substitution with unnatural helix-favoring amino acids, introduction of ion pair interactions, and conjugation of palmitic acid. The resulting 23-mer lipopeptide, termed AEEA-C16, inhibits MERS-CoV S protein-mediated cell-cell fusion at a low micromolar level comparable to that of the 36-mer HR2 peptide HR2P-M2. Collectively, our studies provide new insights into developing short peptide-based antiviral agents to treat MERS-CoV infection.
Insights
Researchers developed a short lipopeptide, AEEA-C16, to inhibit Middle East respiratory syndrome coronavirus (MERS-CoV) fusion. This novel MERS-CoV fusion inhibitor shows potential for treating MERS-CoV infections.
Area of Science:
- Virology
- Structural Biology
- Medicinal Chemistry
Background:
- The Middle East respiratory syndrome coronavirus (MERS-CoV) fusion process is critical for viral entry.
- Interaction between MERS-CoV spike (S) protein's heptad repeat-1 (HR1) and heptad repeat-2 (HR2) domains mediates this fusion.
- The HR2 helix and HR1 hydrophobic groove are key interaction sites.
Purpose of the Study:
- To develop a short peptidomimetic as a MERS-CoV fusion inhibitor.
- To reproduce the key recognition features of the HR2 helix for therapeutic potential.
Main Methods:
- Employed helix-stabilizing strategies, including unnatural amino acids and ion pair interactions.
- Conjugated palmitic acid to create a lipopeptide.
- Tested the resulting 23-mer lipopeptide (AEEA-C16) for MERS-CoV fusion inhibition.
Main Results:
- The lipopeptide AEEA-C16 effectively inhibits MERS-CoV S protein-mediated cell-cell fusion.
- Inhibitory activity was observed at a low micromolar level.
- Performance was comparable to the longer HR2 peptide HR2P-M2.
Conclusions:
- Developed a short, potent lipopeptide inhibitor of MERS-CoV fusion.
- Demonstrated the potential of short peptide-based agents for MERS-CoV treatment.
- Provided insights into designing novel antiviral strategies against MERS-CoV.
